Argos Therapeutics, which is developing immunotherapies for the treatment of cancer and infectious diseases, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Durham, NC-based company, which was founded in 1997 and booked $5 million in collaboration and grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol ARGS. Argos Therapeutics initially filed confidentially on November 12, 2013. Piper Jaffray, Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
